FOLH1 and posterior cortical atrophy: In another, more recent approach, a heterobivalent agent based on a hybrid molecule composed of αvβ3 integrin-specific c(RGDfK) and PSMA-specific iPSMA, being connected by an interpeptidic DOTA-modified cysteine moiety (24), was radiolabeled with 177Lu and evaluated in vitro regarding its applicability for PCa therapy [96].